APA (7th ed.) Citation

Buda, G., Ricci, D., Huang, C. C., Favis, R., Cohen, N., Zhuang, S. H., . . . Orlowski, R. Z. (2010). Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Annals of hematology, 89(11), 1133-1140. https://doi.org/10.1007/s00277-010-0992-3

Chicago Style (17th ed.) Citation

Buda, Gabriele, et al. "Polymorphisms in the Multiple Drug Resistance Protein 1 and in P-glycoprotein 1 Are Associated with Time to Event Outcomes in Patients with Advanced Multiple Myeloma Treated with Bortezomib and Pegylated Liposomal Doxorubicin." Annals of Hematology 89, no. 11 (2010): 1133-1140. https://doi.org/10.1007/s00277-010-0992-3.

MLA (9th ed.) Citation

Buda, Gabriele, et al. "Polymorphisms in the Multiple Drug Resistance Protein 1 and in P-glycoprotein 1 Are Associated with Time to Event Outcomes in Patients with Advanced Multiple Myeloma Treated with Bortezomib and Pegylated Liposomal Doxorubicin." Annals of Hematology, vol. 89, no. 11, 2010, pp. 1133-1140, https://doi.org/10.1007/s00277-010-0992-3.